camptothecin has been researched along with plx4032 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Bollag, G; Bradley, WD; Heimbrook, D; Higgins, B; Kolinsky, K; Kopetz, S; Lee, RJ; Lestini, B; Packman, K; Schostack, K; Simcox, ME; Su, F; Yang, H | 1 |
| Bautista, F; Dufour, C; Geoerger, B; Grill, J; Lacroix, L; Minard-Colin, V; Paci, A; Valteau-Couanet, D; Varlet, P | 1 |
| Imyanitov, EN; Iyevleva, AG; Krasnova, ME; Mitiushkina, NV; Raskin, GA; Silkin, SV; Sokolenko, AP; Startsev, SS | 1 |
| Bardelli, A; Bonaldi, T; Cancelliere, C; Conte, A; Cuomo, A; Di Fiore, PP; Magni, E; Penna, G; Pozzi, C; Ravenda, PS; Rescigno, M; Sigismund, S; Silvola, A; Spadoni, I; Zampino, MG | 1 |
| Atkins, J; Bellido, J; El Osta, B; Fogelman, D; Fu, S; Hong, DS; Huang, H; Janku, F; Kee, B; Kopetz, S; Lanman, R; Meric-Bernstam, F; Morris, VK; Overman, MJ; Piha-Paul, S; Shureiqi, I; Sommer, N; Sorokin, AV; Subbiah, V; Tarcic, G; Tsimberidou, AM | 1 |
| Dai, WP; Jiao, XD; Li, XN; Liu, K; Qin, BD; Qin, WX; Sun, L; Wang, MM; Wang, Z; Ye, CY; Yuan, LY; Zang, YS | 1 |
1 trial(s) available for camptothecin and plx4032
| Article | Year |
|---|---|
Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Proto-Oncogene Proteins B-raf; Vemurafenib | 2022 |
6 other study(ies) available for camptothecin and plx4032
| Article | Year |
|---|---|
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Blotting, Western; Camptothecin; Capecitabine; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Proto-Oncogene Proteins B-raf; Quinazolines; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays | 2012 |
Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Brain Neoplasms; Camptothecin; Cancer Vaccines; Child; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Doxorubicin; Drug Evaluation; Fatal Outcome; Ganglioglioma; Humans; Immunotherapy; Indoles; Infant; Irinotecan; Male; Mutation, Missense; Neoplasm Proteins; Point Mutation; Polyethylene Glycols; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Salvage Therapy; Sulfonamides; Temozolomide; Thalamus; Treatment Outcome; Vemurafenib | 2014 |
Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cholangiocarcinoma; Humans; Indoles; Irinotecan; Male; Mutation; Panitumumab; Sulfonamides; Vemurafenib | 2016 |
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Calreticulin; Camptothecin; Cell Death; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Dendritic Cells; Disease Models, Animal; Endoplasmic Reticulum Stress; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Indoles; Irinotecan; Leucovorin; Mice; Panitumumab; Phagocytosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Sulfonamides; Unfolded Protein Response; Vemurafenib; X-Box Binding Protein 1 | 2016 |
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indoles; Irinotecan; Male; Mice; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins B-raf; Sulfonamides; Survival Analysis; Treatment Outcome; Vemurafenib; Xenograft Model Antitumor Assays | 2016 |
Drug Combo Beats Vemurafenib Alone for Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Humans; Indoles; Irinotecan; Mutation; Proto-Oncogene Proteins B-raf; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome; Vemurafenib | 2017 |